|05/16/17||Coherus BioSciences Prevails in ‘135 IPR Decision|
|Patent Trial and Appeal Board Invalidates AbbVie U.S. Patent 8,889,135
REDWOOD CITY, Calif., May 16, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that the Patent Trial and Appeal Board (“PTAB”) of the U.S. Patent and Trademark Office ruled in favor of Coherus’ petitions for Inter Partes Review (“IPR”) of AbbVie’s U.S. Patent 8,889,135 (the ‘135 Patent). The PTAB’s decision invalidates all claims of the patent that were directed to a method for treating rh... |
|05/08/17||Coherus BioSciences Reports First Quarter 2017 Corporate Highlights and Financial Results|
|REDWOOD CITY, Calif., May 08, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (NASDAQ:CHRS), today reviewed corporate events and reported financial results for the quarter ended March 31, 2017.
Corporate Highlights for the First Quarter 2017 Include:
Immunology (anti-TNF) therapeutic franchise:
CHS-1420 (adalimumab (Humira®) biosimilar candidate)
Reported positive topline 24-week treatment results for CHS-1420 in patients with psoriasis.
Announced filing of four petiti... |
|05/01/17||Coherus BioSciences Management to Present at Two Investor Healthcare Conferences in May|
|REDWOOD CITY, Calif., May 01, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that senior management will present at two upcoming investor healthcare conferences.
A fireside chat is scheduled at Deutche Bank’s 42nd Annual Health Care Conference on Wednesday, May 3rd at 10:40 a.m. EDT taking place in Boston, MA.
A company presentation is scheduled at the Bank of America/Merrill Lynch Healthcare Conference on Thursday, May 18th at 8:40 a.m. PDT taking ... |
|04/25/17||Coherus BioSciences Completes Patent Dance Exchange with Amgen for Neulasta Biosimilar|
|REDWOOD CITY, Calif., April 25, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), announced today that it completed the initial phases of the Biologics Price Competition and Innovation Act (BPCIA) patent exchange procedure with Amgen for Coherus’ Neulasta (pegfilgrastim) biosimilar candidate, CHS-1701. Of the two patents originally listed by Amgen in the process, the parties have reached agreement on a single patent for potential litigation, U.S. patent 8,273,707 (the ‘707 pat... |